Guardant Health/$GH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Guardant Health
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Ticker
$GH
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
2,010
ISIN
US40131M1099
Website
Guardant Health Metrics
BasicAdvanced
$5.9B
-
-$3.38
1.45
-
Price and volume
Market cap
$5.9B
Beta
1.45
52-week high
$52.92
52-week low
$20.14
Average daily volume
2.5M
Financial strength
Current ratio
4.106
Quick ratio
3.606
Long term debt to equity
-509.08
Total debt to equity
-509.08
Interest coverage (TTM)
-166.70%
Management effectiveness
Return on assets (TTM)
-18.65%
Return on equity (TTM)
456.48%
Valuation
Price to revenue (TTM)
7.607
Price to book
-23.55
Price to tangible book (TTM)
-22.68
Price to free cash flow (TTM)
-19.313
Growth
Revenue change (TTM)
28.20%
Earnings per share change (TTM)
-14.41%
3-year revenue growth (CAGR)
25.55%
3-year earnings per share growth (CAGR)
-6.47%
What the Analysts think about Guardant Health
Analyst ratings (Buy, Hold, Sell) for Guardant Health stock.
Guardant Health Financial Performance
Revenues and expenses
Guardant Health Earnings Performance
Company profitability
Guardant Health News
AllArticlesVideos
Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?
Benzinga·3 days ago
FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test
Business Wire·3 days ago
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening
Business Wire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Guardant Health stock?
Guardant Health (GH) has a market cap of $5.9B as of June 06, 2025.
What is the P/E ratio for Guardant Health stock?
The price to earnings (P/E) ratio for Guardant Health (GH) stock is 0 as of June 06, 2025.
Does Guardant Health stock pay dividends?
No, Guardant Health (GH) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Guardant Health dividend payment date?
Guardant Health (GH) stock does not pay dividends to its shareholders.
What is the beta indicator for Guardant Health?
Guardant Health (GH) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.